Metamizol Stada (Metamizole Sodium Monohydrate)

Metamizole sodium works by non‑selectively inhibiting cyclooxygenase enzymes, which lowers prostaglandin production. This results in central analgesic effects and spasmolytic activity that help alleviate pain and reduce fever.

The appropriate dose of Metamizol Stada is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and clinical response. Dosage instructions are provided on the prescription label.

Safety data for metamizole sodium in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Metamizol Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizol Stada belongs to the pyrazolone class, offering strong analgesic and antipyretic effects with a spasmolytic component. Compared with traditional NSAIDs, it may have a lower risk of gastrointestinal irritation but carries a rare risk of severe blood‑cell disorders, requiring regular monitoring.

Metamizol Stada should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat.

Metamizol Stada is administered orally. The tablet is swallowed whole with water, unless otherwise directed by a healthcare professional. It should be taken with or without food as advised by the prescriber.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. Prompt medical attention is required if any signs of these conditions appear.

Metamizol Stada should be avoided in patients with known hypersensitivity to metamizole or other pyrazolones, those with severe liver or kidney impairment, and individuals with a history of blood‑cell disorders. It is also contraindicated in patients taking certain interacting medications without close monitoring.